Evidence map›Paper›PMID 25304929›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2014

Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database.

Emma H Allott, Lauren E Howard, Matthew R Cooperberg, Christopher J Kane, William J Aronson, Martha K Terris, Christopher L Amling, Stephen J Freedland

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06661044 (Exploiting Human Microbiota-associated in Vivo Models for Mechanistic Studies to Understand the Benefits of Dietary Fibre Supplementation in Patients With Prostate Cancer), which is not on this map. Cited by 89 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 4 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06661044 completednot on this mapstarted 2024, after this paper: background citation

Exploiting Human Microbiota-associated in Vivo Models for Mechanistic Studies to Understand the Benefits of Dietary Fibre Supplementation in Patients With Prostate Cancer

TypeobservationalSponsorUniversity of AberdeenRan2024 to 2025Enrolled6ConditionsProstate Cancer (Adenocarcinoma)
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 4 syntheses or guidelines pooled it, 155 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. 27-Hydroxycholesterol in cancer development and drug resistance.Journal of enzyme inhibition and medicinal chemistry · 2025
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Emma H AllottDivision of Urology, Department of Surgery, Duke University School of Medicine, Durham, North Carolina. Cancer Prevention, Detection, and Control Program, Duke Cancer Institute, Durham, North Carolina. Division of Urology, Veterans Affairs Medical Center Durham, Durham, North Carolina.
Lauren E HowardDivision of Urology, Department of Surgery, Duke University School of Medicine, Durham, North Carolina. Division of Urology, Veterans Affairs Medical Center Durham, Durham, North Carolina. Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina.
Matthew R CooperbergDepartment of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Christopher J KaneUrology Department, University of California San Diego Health System, San Diego, California.
William J AronsonUrology Section, Department of Surgery, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California. Department of Urology, UCLA School of Medicine, Los Angeles, California.
Martha K TerrisSection of Urology, Veterans Affairs Medical Center, Augusta, Georgia. Section of Urology, Medical College of Georgia, Augusta, Georgia.
Christopher L AmlingDivision of Urology, Oregon Health and Science University, Portland, Oregon.
Stephen J FreedlandDivision of Urology, Department of Surgery, Duke University School of Medicine, Durham, North Carolina. Division of Urology, Veterans Affairs Medical Center Durham, Durham, North Carolina. Department of Pathology, Duke University School of Medicine, Durham, North Carolina. steve.freedland@duke.edu.
Duke University · USAugusta University · USOregon Health & Science University · USUC San Diego Health System · USUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of California, Los Angeles · US

Funding

Integrating Population and Basic Science in Cancer ResearchR25CA126938 · NCI · DUKE UNIVERSITY · PI SCHILDKRAUT, JOELLEN M. · 2009 to 2013
$1.7M
Resveratrol, Carbohydrate Restriction and Prostate Cancer ProgressionR01CA131235 · NCI · DUKE UNIVERSITY · PI FREEDLAND, STEPHEN JAY, PIZZO, SALVATORE V · 2008 to 2012
$1.5M
Midcareer Investigator AwardK24CA160653 · NCI · DUKE UNIVERSITY · PI FREEDLAND, STEPHEN JAY · 2012 to 2016
$877k
NCI NIH HHS 1K24CA160653NCI NIH HHS 1-R01-CA131235-01A1NCI NIH HHS 5R25-CA126938-03NCI NIH HHS K24 CA160653NCI NIH HHS R01 CA131235NCI NIH HHS R25 CA126938
6 · The paper itself

Abstract

backgroundEvidence for an association between total cholesterol, low- and high-density lipoproteins (LDL and HDL, respectively), triglycerides, and prostate cancer is conflicting. Given that prostate cancer and dyslipidemia affect large proportions of Western society, understanding these associations has public health importance.

methodsWe conducted a retrospective cohort analysis of 843 radical prostatectomy (RP) patients who never used statins before surgery within the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Multivariable Cox proportional hazards analysis was used to investigate the association between cholesterol, LDL, HDL, and triglycerides and biochemical recurrence risk. In secondary analysis, we explored these associations in patients with dyslipidemia, defined using National Cholesterol Education Program guidelines.

resultsElevated serum triglycerides were associated with increased risk of prostate cancer recurrence [HRper 10 mg/dl, 1.03; 95% confidence interval (CI), 1.01-1.05] but associations between total cholesterol, LDL and HDL, and recurrence risk were null. However, among men with dyslipidemia, each 10 mg/dl increase in cholesterol and HDL was associated with 9% increased recurrence risk (HR, 1.09; 95% CI, 1.01-1.17) and 39% reduced recurrence risk (HR, 0.61; 95% CI, 0.41-0.91), respectively.

conclusionsElevated serum triglycerides were associated with increased risk of prostate cancer recurrence. Cholesterol, LDL, or HDL were not associated with recurrence risk among all men. However, among men with dyslipidemia, elevated cholesterol and HDL levels were associated with increased and decreased risk of recurrence, respectively. IMPACT: These findings, coupled with evidence that statin use is associated with reduced recurrence risk, suggest that lipid levels should be explored as a modifiable risk factor for prostate cancer recurrence.

Indexed as

AgedCholesterolDatabases, FactualDyslipidemiasFollow-Up StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsLipoproteins, HDLLipoproteins, LDLMaleMiddle AgedNeoplasm Recurrence, LocalProstatectomyProstate-Specific AntigenProstatic NeoplasmsCholesterolHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsLipoproteins, HDLLipoproteins, LDLProstate-Specific AntigenTriglycerides

Identifiers

PMID25304929
PMCPMC4221498
OpenAlexW2010062788

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.